Related Experiment Video

Updated: Jul 10, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS

A Cyniak-Magierska1, E Brzeziańska, J Januszkiewicz-Caulier

  • 1Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|October 19, 2007
PubMed

Insights

This study investigated RAS oncogene mutations in papillary thyroid carcinoma (PTC), finding mutations rarely occur in PTC compared to follicular neoplasms. Further research is needed on a novel K-RAS mutation

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Papillary thyroid carcinoma (PTC) is a common endocrine malignancy.
  • RAS oncogenes are frequently mutated in various cancers, but their role in PTC is less understood.
  • Previous studies suggest RAS mutations are less frequent in PTC than in follicular thyroid neoplasms.

Purpose of the Study:

  • To determine the incidence of point mutations in RAS oncogenes (H-RAS, K-RAS, N-RAS) in papillary thyroid carcinoma.
  • To compare the frequency of RAS mutations in PTC with that in follicular neoplasms.
  • To investigate a novel K-RAS mutation identified in PTC.

Main Methods:

  • Tumor specimens from 29 PTC cases were analyzed.
  • Exons 1 and 2 of H-RAS, K-RAS, and N-RAS oncogenes were amplified.
  • Point mutations were detected using Single-Strand Conformation Polymorphism (SSCP) and/or Restriction Fragment Length Polymorphism (RFLP) analysis.
  • Direct sequencing was used for confirmation of detected mutations.

Main Results:

  • Two mutations were identified: a K-RAS mutation at codon 31 (GAA/CAA) and an N-RAS mutation at codon 61 (CAA/CAC).
  • The incidence of RAS mutations in PTC was found to be low.
  • RAS mutations were confirmed to be rarer in PTC than in follicular neoplasms.

Conclusions:

  • RAS oncogene mutations are infrequently detected in papillary thyroid carcinoma.
  • The findings support previous evidence indicating a lower prevalence of RAS mutations in PTC compared to follicular thyroid neoplasms.
  • The clinical significance and impact of the novel K-RAS mutation at codon 31 on PTC development require further investigation.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...